Inventor
FAUCETTE RYAN
US18 patents
⚠️ This page may combine multiple inventors who share the name “FAUCETTE RYAN”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
TAKEDA PHARMACEUTICALS CO
14 patentsUS11084884B2Aug 10, 2021
Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema
TAKEDA PHARMACEUTICALS CO23 citations91
US11372002B2Jun 28, 2022
Assays for determining plasma kallikrein system biomarkers
TAKEDA PHARMACEUTICALS CO9 citations84
US11340237B2May 24, 2022
Metabolite biomarkers for diseases associated with the contact activation system
TAKEDA PHARMACEUTICALS CO7 citations83
US11458477B2Oct 4, 2022
Evacuated blood collection tubes containing protease inhibitors for the assessment of contact system activation
TAKEDA PHARMACEUTICALS CO1 citations72
US11156612B2Oct 26, 2021
Methods of determining levels of cleaved and/or intact kininogen
TAKEDA PHARMACEUTICALS CO6 citations71
US11668718B2Jun 6, 2023
Peptide quantitation assay for differentiating full-length high molecular weight kininogen (HMWK) and cleaved HMWK
TAKEDA PHARMACEUTICALS CO2 citations68
US11826758B2Nov 28, 2023
Evacuated blood collection tubes containing protease inhibitors for the assessment of contact system activation
TAKEDA PHARMACEUTICALS CO0 citations62
US12442824B2Oct 14, 2025
Assays for determining plasma kallikrein system biomarkers
TAKEDA PHARMACEUTICALS CO0 citations61
US12384854B2Aug 12, 2025
Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema
TAKEDA PHARMACEUTICALS CO1 citations61
US12493047B2Dec 9, 2025
Cleaved high molecule weight kininogen (HMWK) antibodies and methods of using
TAKEDA PHARMACEUTICALS CO0 citations60
US12188948B2Jan 7, 2025
Metabolite biomarkers for diseases associated with the contact activation system
TAKEDA PHARMACEUTICALS CO0 citations60
US11884979B2Jan 30, 2024
RNA biomarkers for hereditary angioedema
TAKEDA PHARMACEUTICALS CO0 citations60
US11815516B2Nov 14, 2023
Protein biomarkers for diseases associated with the contact activation system
TAKEDA PHARMACEUTICALS CO0 citations60
US12135329B2Nov 5, 2024
Peptide quantitation assay for differentiating full-length high molecular weight kininogen (HMWK) and cleaved HMWK
TAKEDA PHARMACEUTICALS CO0 citations58